{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:27:34Z","timestamp":1783974454284,"version":"3.55.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Insulin is a mainstay treatment for diabetes, but its use is associated with weight gain and hypoglycaemia. Data on the effects of sodium\u2013glucose co-transporter 2 (SGLT2) inhibitors on insulin use in people with chronic kidney disease (CKD) are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a post hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial. Effects of canagliflozin versus placebo on insulin use (initiation, dose intensification, reduction and discontinuation) in people with CKD and type 2 diabetes were evaluated using Cox regression models. The primary outcome was insulin initiation or a &amp;gt;25% insulin dose intensification (in those not receiving and receiving insulin at baseline, respectively). Effects on kidney, cardiovascular and safety outcomes by baseline insulin use were also assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 4401 participants, 2884 (65.5%) were receiving insulin at baseline; these participants were more likely to have lower estimated glomerular filtration rate, higher albuminuria and a longer duration of diabetes (all P\u00a0&amp;lt;\u00a0.001). Over a median on-treatment period of 2.0\u00a0years, canagliflozin reduced the need for insulin initiation or a &amp;gt;25% dose intensification by 19% compared with placebo {hazard ratio [HR] 0.81 [95% confidence interval (CI) 0.71\u20130.93]}, irrespective of baseline kidney function or albuminuria (both P-interaction\u00a0&amp;gt;\u00a0.10). Sustained insulin dose reductions of &amp;gt;50% were achieved more frequently with canagliflozin than placebo [HR 1.49 (95% CI 1.15\u20131.91)], although no difference in insulin discontinuation was observed between treatment arms. Effects of canagliflozin on kidney, cardiovascular and safety outcomes were consistent regardless of baseline insulin use (all P-interaction\u00a0&amp;gt;\u00a0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In CKD and type 2 diabetes, canagliflozin reduces insulin use with consistent effects regardless of baseline kidney function. This supports the use of canagliflozin in people with CKD, not only for end-organ protection, but also to improve glycaemic control and reduce exposure to insulin and its associated adverse effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf044","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T17:32:36Z","timestamp":1741109556000},"page":"1727-1735","source":"Crossref","is-referenced-by-count":3,"title":["Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5697-4563","authenticated-orcid":false,"given":"Bryony","family":"Beal","sequence":"first","affiliation":[{"name":"Royal North Shore Hospital Department of Renal Medicine, , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Buizen","sequence":"additional","affiliation":[{"name":"University of New South Wales George Institute for Global Health, , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K","family":"Yeung","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas\u2019 NHS Foundation Trust Department of Nephrology and Transplantation, , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Heath","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital Department of Renal Medicine, , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Houston","sequence":"additional","affiliation":[{"name":"University of New South Wales George Institute for Global Health, , Sydney, NSW ,","place":["Australia"]},{"name":"University of New South Wales Faculty of Medicine and Health, , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z I","family":"Cherney","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Department of Medicine, Division of Nephrology, , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Jardine","sequence":"additional","affiliation":[{"name":"University of New South Wales George Institute for Global Health, , Sydney, NSW ,","place":["Australia"]},{"name":"University of Sydney NHMRC Clinical Trials Centre, , Sydney, NSW ,","place":["Australia"]},{"name":"Concord Repatriation and General Hospital Department of Renal Medicine, , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-6495","authenticated-orcid":false,"given":"Carol","family":"Pollock","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital Department of Renal Medicine, , Sydney, NSW ,","place":["Australia"]},{"name":"University of Sydney Kolling Institute, , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9370-9913","authenticated-orcid":false,"given":"Clare","family":"Arnott","sequence":"additional","affiliation":[{"name":"University of New South Wales George Institute for Global Health, , Sydney, NSW ,","place":["Australia"]},{"name":"University of New South Wales Faculty of Medicine and Health, , Sydney, NSW ,","place":["Australia"]},{"name":"Royal Prince Alfred Hospital Department of Cardiology, , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sradha S","family":"Kotwal","sequence":"additional","affiliation":[{"name":"University of New South Wales George Institute for Global Health, , Sydney, NSW ,","place":["Australia"]},{"name":"Prince of Wales Hospital Department of Renal Medicine, , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"University of New South Wales George Institute for Global Health, , Sydney, NSW ,","place":["Australia"]},{"name":"University Medical Centre Groningen Department of Clinical Pharmacy and Pharmacology, University of Groningen, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"University of New South Wales George Institute for Global Health, , Sydney, NSW ,","place":["Australia"]},{"name":"University of New South Wales Faculty of Medicine and Health, , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L","family":"Neuen","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital Department of Renal Medicine, , Sydney, NSW ,","place":["Australia"]},{"name":"University of New South Wales George Institute for Global Health, , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"2025082900420271400_bib1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"2025082900420271400_bib2","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2337\/dc17-2677","article-title":"Hypoglycaemia, cardiovascular outcomes, and death: the LEADER experience","volume":"41","author":"Zinman","year":"2018","journal-title":"Diabetes Care"},{"key":"2025082900420271400_bib3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"Suppl 121","key":"2025082900420271400_bib4","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","volume":"79","author":"List","year":"2011","journal-title":"Kidney Int"},{"key":"2025082900420271400_bib5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2025082900420271400_bib6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2025082900420271400_bib7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2025082900420271400_bib8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2025082900420271400_bib9","doi-asserted-by":"publisher","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"5 Suppl","key":"2025082900420271400_bib10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guidelines for diabetes management in chronic kidney disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"2025082900420271400_bib11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025082900420271400_bib12","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1681\/ASN.0000000000000248","article-title":"Effect of SGLT2 inhibitors on discontinuation of renin\u2013angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials","volume":"34","author":"Fletcher","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025082900420271400_bib13","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1111\/dom.14535","article-title":"Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: findings from the EMPA-REG OUTCOME trial","volume":"23","author":"Vaduganathan","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025082900420271400_bib14","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/clinem\/dgac764","article-title":"Ertugliflozin delays insulin initiation and reduces insulin dose requirements in patients with type 2 diabetes: analyses from VERTIS CV","volume":"108","author":"Dagogo-Jack","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2025082900420271400_bib15","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1111\/dom.14385","article-title":"Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: a VERTIS CV substudy","volume":"23","author":"Lingvay","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025082900420271400_bib16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/dom.14691","article-title":"Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: an analysis from VERTIS CV","volume":"24","author":"Dagogo-Jack","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2025082900420271400_bib17","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1111\/dom.15572","article-title":"Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: an EMPEROR-Pooled analysis","volume":"26","author":"Talha","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025082900420271400_bib18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S0735-1097(23)00722-2","article-title":"The effect of dapagliflozin on insulin initiation or intensification in patients in heart failure and diabetes: a pooled analysis of DAPA-HF and DELIVER","volume":"81","author":"McMurray","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025082900420271400_bib19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2337\/dc22-1514","article-title":"Efficacy of dapagliflozin by baseline diabetes medications: a prespecified analysis from the DAPA-CKD study","volume":"46","author":"Beernink","year":"2023","journal-title":"Diabetes Care"},{"key":"2025082900420271400_bib20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr Diab Rep"},{"key":"2025082900420271400_bib21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"2025082900420271400_bib22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"2025082900420271400_bib23","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf044\/62208064\/gfaf044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/9\/1727\/62208064\/gfaf044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/9\/1727\/62208064\/gfaf044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T04:42:07Z","timestamp":1756442527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/9\/1727\/8046433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,2,28]]},"published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf044","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,2,28]]}}}